HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Proposal For Increased Sunscreen Safety Testing On NDAC Agenda

This article was originally published in The Rose Sheet

Executive Summary

FDA’s Nonprescription Drug Advisory Committee will consider proposed tests for evaluating the safety of sunscreen ingredients that sponsors want to add to the OTC monograph. The committee will not consider the safety or efficacy of specific ingredients pending review via TEAs.

You may also be interested in...

Sunscreen Safety Framework Is FDA’s First Step, With More Tests Needed – NDAC

NDAC members agree with FDA’s proposed standards for evaluating the safety of sunscreen monograph ingredients, but suggest the agency add tests to evaluate the impact of long-term use, actual use and bioavailability in specific populations.

Existing Sunscreen Monograph Ingredients Could Fail Proposed Safety Standards

FDA’s proposed safety standards for sunscreen monograph ingredients might not align with safety evidence supporting current monograph ingredients. Without a safeguard, such as a grandfather clause, these ingredients could face challenges if FDA adopts stricter standards, NDAC committee members worry.

L’Oreal Sunscreen TEA Falls Short On Safety, Efficacy, AE Data

Ahead of NDAC’s discussion of tests for evaluating the safety of sunscreen ingredients, FDA issues its fourth letter this year to sunscreen TEA applicants citing insufficient data. FDA says it needs additional data on safety, efficacy and adverse events from L’Oreal to determine GRASE for drometrizole trisiloxane, marketed as Mexoryl XL.

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts